SCHEMBL2651032

SCHEMBL2651032

O=C(Nc1nccs1)C(=Cc1cccs1)c1ccc(Br)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.80
NPC1 O15118 11/20 0.60
RAB9A P51151 11/20 0.60
KMT2A Q03164 5/20 0.60
MEN1 O00255 4/20 0.60
SMN1; SMN2 Q16637 7/20 0.58
ALDH1A1 P00352 3/20 0.58
MAPT P10636 2/20 0.58
POLB P06746 1/20 0.58
KDM4E B2RXH2 2/20 0.53
STAT1 P42224 1/20 0.49
LMNA P02545 3/20 0.46
GAA P10253 2/20 0.46
SCD O00767 1/20 0.45
MGAM O43451 1/20 0.45
SI P14410 1/20 0.45
MGAM2 Q2M2H8 1/20 0.45
RECQL P46063 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651028 1.00 GCK (0.80) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL2649852 0.89 GCK (1.00) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL2649857 0.89 GCK (1.00) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL9071928 0.88 GCK (0.80) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL9071862 0.88 GCK (0.80) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL2649917 0.87 GCK (0.74) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL2649915 0.87 GCK (0.74) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL2651637 0.86 GCK (0.60) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL2651640 0.86 GCK (0.60) GCKNPC1RAB9AKMT2AMEN1
SCHEMBL2650693 0.85 GCK (0.64) GCKNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP claimed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US claimed
EP-1594867-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2005-11-16 EP claimed
US-20040181067-A1 Tri(cyclo) substituted amide compounds OSI PHARMACEUTICALS, INC. 2004-09-16 US claimed
WO-2004072031-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS PROSIDION LIMITED (GB) 2004-08-26 WO claimed
EP-2168962-A2 PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS Prosidion Limited (GB) 2010-03-31 EP disclosed
US-7582632-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2009-09-01 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
US-7214681-B2 Tri(cyclo) substituted amide compounds PROSIDION LIMITED (GB) 2007-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181067-A1 Tri(cyclo) substituted amide compounds GPR119, IAPP, SLC5A1 GCK 60/4885NPC1 543/4885RAB9A 3333/4885
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS IAPP, GPR119, SLC5A1 GCK 70/4885NPC1 733/4885RAB9A 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.